Scancell

Scancell, based in Oxford, the United Kingdom, is a biotechnology company. Scancell is a late-stage clinical company developing active immunotherapies designed to enhance anti-tumour immune responses in cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in melanoma, triple-negative breast cancer, renal cell carcinoma, ovarian cancer and head and neck squamous cell carcinoma. The largest, NCT04079166 (SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)), plans to enrol 173 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.